These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37094656)

  • 21. HER-2/neu amplification and overexpression in endometrial carcinoma.
    Rolitsky CD; Theil KS; McGaughy VR; Copeland LJ; Niemann TH
    Int J Gynecol Pathol; 1999 Apr; 18(2):138-43. PubMed ID: 10202671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.
    Guo L; Yuan P; Zhang J; Ling Y; Li W; Zhao B; Ying J; Xuan L
    Breast Cancer Res Treat; 2017 Nov; 166(1):77-84. PubMed ID: 28712009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor.
    Liu Y; Wu S; Shi X; Luo Y; Pang J; Wang C; Mao F; Liang Z; Zeng X
    Breast Cancer Res Treat; 2019 Nov; 178(2):275-281. PubMed ID: 31388934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer.
    Pu X; Shi J; Li Z; Feng A; Ye Q
    Pathol Res Pract; 2015 Jun; 211(6):421-5. PubMed ID: 25818873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER2 Expression in Endometrial Cancers Diagnosed as Clear Cell Carcinoma.
    Cagaanan A; Stelter B; Vu N; Rhode EN; Stewart T; Hui P; Buza N; Al-Niaimi A; Flynn C; Weisman PS; McGregor SM
    Int J Gynecol Pathol; 2022 Mar; 41(2):132-141. PubMed ID: 33782344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method.
    Sapino A; Maletta F; Verdun di Cantogno L; Macrì L; Botta C; Gugliotta P; Scalzo MS; Annaratone L; Balmativola D; Pietribiasi F; Bernardi P; Arisio R; Viberti L; Guzzetti S; Orlassino R; Ercolani C; Mottolese M; Viale G; Marchiò C
    Oncologist; 2014 Nov; 19(11):1118-26. PubMed ID: 25323485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
    Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
    Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The statuses of HER2 expression and mismatch repair in endometrial clear cell carcinoma.
    Bayramoglu Z; Erozbek SY; Ozdemir IA; Ulker V; Muezzinoglu B
    Pathol Res Pract; 2023 Jan; 241():154258. PubMed ID: 36516643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy.
    Yoshida H; Nishikawa T; Matsumoto K; Mori M; Hirashima Y; Takehara K; Ariyoshi K; Hasegawa K; Yonemori K
    Virchows Arch; 2021 Jun; 478(6):1161-1171. PubMed ID: 33423127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
    Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
    Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
    Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma.
    Buza N; Hui P
    Genes Chromosomes Cancer; 2013 Dec; 52(12):1178-86. PubMed ID: 24123408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data.
    Stoss OC; Scheel A; Nagelmeier I; Schildhaus HU; Henkel T; Viale G; Jasani B; Untch M; Rüschoff J
    Mod Pathol; 2015 Dec; 28(12):1528-34. PubMed ID: 26403781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility.
    Moktefi A; Pouessel D; Liu J; Sirab N; Maille P; Soyeux P; Bergman CC; Auriault ML; Vordos D; Taille A; Culine S; Allory Y
    Mod Pathol; 2018 Aug; 31(8):1270-1281. PubMed ID: 29467478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
    Middleton LP; Price KM; Puig P; Heydon LJ; Tarco E; Sneige N; Barr K; Deavers MT
    Arch Pathol Lab Med; 2009 May; 133(5):775-80. PubMed ID: 19415952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy.
    Klc TR; Wu S; Wilhite AM; Jones NL; Powell MA; Olawaiye A; Girda E; Brown J; Puechl A; Ali-Fehmi R; Winer IS; Herzog TJ; Korn WM; Erickson BK
    Gynecol Oncol; 2022 Nov; 167(2):289-294. PubMed ID: 36114027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
    Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing.
    Ferguson DC; Momeni Boroujeni A; Zheng T; Mohanty AS; Ho AL; Arcila ME; Ross DS; Dogan S
    Mod Pathol; 2022 Jul; 35(7):895-902. PubMed ID: 34963694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER2 Overexpression and Amplification in Uterine Carcinosarcomas With Serous Morphology.
    Jenkins TM; Cantrell LA; Stoler MH; Mills AM
    Am J Surg Pathol; 2022 Apr; 46(4):435-442. PubMed ID: 35125452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features.
    Stewart RL; Caron JE; Gulbahce EH; Factor RE; Geiersbach KB; Downs-Kelly E
    Mod Pathol; 2017 Nov; 30(11):1561-1566. PubMed ID: 28752841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.